pyruvic acid has been researched along with imatinib mesylate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brabcova, Z; Copland, M; Dawson, A; de Beauchamp, L; Dunn, K; Gottlieb, E; Ianniciello, A; Kalkman, ER; Khalaf, A; Kwan, R; Michie, AM; Rattigan, KM; Roy, K; Sarnello, D; Scott, MT; Sumpton, D; Tardito, S; Vignir Helgason, G; Zarou, MM | 1 |
1 other study(ies) available for pyruvic acid and imatinib mesylate
| Article | Year |
|---|---|
Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.
Topics: Acclimatization; Biological Assay; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyruvic Acid | 2023 |